Full Press Release Details
Kamada to Announce Fourth Quarter and Fiscal
Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
Company to Host Conference Call at 8:30am ET
Rehovot, Israel, and Hoboken, NJ, February
28, 2024 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed
products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release
financial results for the fourth quarter and fiscal year ended December 31, 2023, as well as provide 2024 financial guidance, prior to
the open of the U.S. financial markets on Wednesday, March 6, 2024.
management will host an investment community conference call on Wednesday, March 6, at 8:30am Eastern Time to discuss these results and
answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within
the U.S.), 1-809-406-247 (from Israel) or 1 201-689-8263 (International) using conference
ID 13744277. The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1655132&tp_key=6e560eef4a.
will also be archived for 90 days on the Company's website at www.kamada.com.
Kamada Ltd. (the "Company") is a commercial
stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in
the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative
development pipeline targeting areas of significant unmet medical need. The Company's strategy is focused on driving profitable
growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical
fields. The Company's commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: KEDRAB ,
CYTOGAM , VARIZIG , WINRHO SDF , HEPAGAM B and GLASSIA , as well as KAMRAB , KAMRHO (D) and two types of
equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic
partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India,
Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in
the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers
and in addition have eleven biosimilar products in its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA)
and Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma
collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of
KAMRHO (D), KAMRAB and KEDRAB. In addition to the Company's commercial operation, it invests in research and development of new
product candidates. The Company's leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which
it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI
Opportunity Funds, the leading private equity firm in Israel, is the Company's controlling shareholder, beneficially owning
approximately 38% of the outstanding ordinary shares.
Chief Financial Officer
LifeSci Advisors, LLC